A gout diagnosis is both a relief (you finally know what's causing the pain) and a call to action. Without proper management — both clinical and financial — gout becomes a recurrent, worsening condition. Here's how to handle your medical aid from day one.
The Honest Starting Point
Gout is not a PMB or CDL condition. Your scheme is not legally required to fund any specific gout treatment as a minimum benefit. All costs — consultations, medication, blood tests — come from your day-to-day benefit, MSA, or ATB.
The good news: the cornerstone long-term treatment (allopurinol) is one of the cheapest chronic medications available in SA, at R50–R150/month generic. Managing gout well is highly cost-effective if you do it correctly.
Step 1: Confirm Your Diagnosis Is Properly Documented
Gout is ideally confirmed by synovial fluid analysis (joint aspiration demonstrating monosodium urate crystals). In practice, many SA GPs diagnose clinically (classic presentation + elevated serum uric acid + response to colchicine). Whatever the diagnostic method, ensure:
- Your diagnosis is documented in your medical records as gout (ICD-10: M10.x).
- Your treating doctor has recorded the diagnosis in the records they submit to medical aid. This affects how consultations are coded.
- If your GP is uncertain, request a rheumatologist referral — joint aspiration provides definitive diagnosis and rules out septic arthritis (a dangerous mimic).
Step 2: Understand Acute Flare Treatment — What's Available
For acute attacks, your options funded through day-to-day benefits are:
Colchicine: First-line preferred treatment. Highly effective when started within 12–24 hours of flare onset. Generic is available (R200–R600 per course). Confirm availability at your preferred pharmacy.
NSAIDs (indomethacin, naproxen, ibuprofen): Also effective; use with caution if you have renal impairment or hypertension. Widely available, inexpensive.
Corticosteroids (prednisolone, methylprednisolone): Used when colchicine/NSAIDs are contraindicated. R100–R300 per course.
Practical tip: Stock colchicine at home. The sooner you take it in a flare, the more effective it is. Ask your doctor to prescribe a course to keep on hand.
Step 3: Start Urate-Lowering Therapy — The Key Long-Term Move
If you've had two or more gout attacks, have tophi, or have elevated uric acid with comorbidities (CKD, kidney stones, hypertension), urate-lowering therapy (ULT) is indicated. This is where long-term cost management starts.
Allopurinol (generic): Standard first-line ULT. Generic is ~R50–R150/month. Aim for a target serum uric acid <360 µmol/L. Start at a low dose and titrate gradually — starting ULT during a flare or at too high a dose can paradoxically trigger attacks.
Febuxostat: Alternative for allopurinol intolerance or CKD. More expensive (~R400–R700/month). Check whether your scheme classifies it differently from allopurinol.
Call your scheme and ask: "Is allopurinol (febuxostat if applicable) covered under my acute medication benefit or chronic medicine benefit?"
If chronic, you may qualify for a 3-month supply dispensing arrangement, which reduces dispensing fees and ensures continuity of supply.
Step 4: Register Comorbidities on CDL
If you have gout alongside hypertension, type 2 diabetes, dyslipidaemia, or chronic kidney disease, these are CDL-listed conditions. CDL registration means your chronic medication for these conditions is funded from a dedicated CDL benefit — not your MSA.
This is critical: Hypertension is treated with diuretics in many patients. Thiazide diuretics raise serum uric acid and worsen gout. If you're on a thiazide for hypertension, ask your doctor whether switching to an alternative antihypertensive (e.g., losartan, which actually lowers uric acid) is appropriate. Ensure your CDL registration is current.
Step 5: Know Your Sub-Limits
Gout is typically GP-manageable for most patients. However, if you require rheumatologist input (refractory gout, uncertain diagnosis, significant comorbidities), specialist visits cost R1,200–R2,500+ per consultation and are funded from your day-to-day or specialist benefit.
Ask: "What is my annual specialist consultation sub-limit, and how many specialist visits does it accommodate?"
For most plans, 2–4 rheumatologist visits per year will exhaust a limited specialist sub-limit. If your plan has a limited sub-limit, consider whether a comprehensive pathology workup at the first visit (uric acid, renal function, full blood count, lipids) avoids the need for multiple visits.
Step 6: Monitor Uric Acid and Renal Function
Gout management requires ongoing laboratory monitoring: - Serum uric acid (target <360 µmol/L) — every 3–6 months until stable - Renal function (eGFR, creatinine, urea) — annually or more frequently if CKD - Liver function tests — if on febuxostat
These are funded from your pathology benefit. Most plans include a reasonable annual pathology allowance. Check whether your plan requires pathology to be done at a designated DSP laboratory (e.g., Ampath, Lancet, Pathcare — typically contracted at 100% tariff; private labs may bill above tariff).
Step 7: Dietary and Lifestyle Changes — Funded?
Dietary advice from a registered dietitian is the ideal complement to medical management. Dietitian visits are typically day-to-day funded with a limited number of sessions per year. Ask: "How many dietitian visits does my plan cover annually?"
Dietary changes that reduce gout risk: reduce red meat, organ meat, shellfish, and beer; increase water intake; limit fructose-containing soft drinks; reduce alcohol generally.
Support Resource
South African Rheumatism and Arthritis Association (SARAA): saraa.co.za
Talk to Eldon
If gout management is straining your day-to-day benefit, the Check shows what each plan pays for day-to-day care, side by side, and Eldon advises from there.
Review your plan for chronic condition management →